
|Articles|December 18, 2014
- Breast Cancer (Issue 1)
- Volume 1
- Issue 1
Immune Checkpoint Inhibition in Breast Cancer
Author(s)Edith A. Perez, MD
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
<<<
Articles in this issue
almost 11 years ago
Breast Ultrasound Added to Mammography Increases Cancer Detectionalmost 11 years ago
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debutedalmost 11 years ago
Anti-Androgen Not for Male Cancers Alonealmost 11 years ago
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBCalmost 11 years ago
Obesity as a Risk Factor for Inflammatory Breast Canceralmost 11 years ago
Advances in the Treatment of HER2-Positive Breast CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
NCCN Guidelines in nccRCC Weigh New Data for Combinations
3
CARTITUDE-4: Cilta-Cel May Offer Curative Potential in Standard-Risk R/R Myeloma
4
Microbiota-Based MaaT013 Shows Strong Efficacy in Refractory GI-aGVHD
5









































